Bladder Cancer Clinical Trial

Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers

Summary

This exploratory study investigates how an imaging technique called 68Ga-FAPi-46 PET/CT can determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with cancer. Because some cancers take up 68Ga-FAPi-46 it can be seen with PET. FAP stands for Fibroblast Activation Protein. FAP is produced by cells that surround tumors (cancer associated fibroblasts). The function of FAP is not well understood but imaging studies have shown that FAP can be detected with FAPI PET/CT. Imaging FAP with FAPI PET/CT may in the future provide additional information about various cancers.

View Full Description

Full Description

PRIMARY OBJECTIVE:

I. To define the biodistribution of gallium Ga 68 fibroblast activation protein inhibitor (FAPi)-46 (68Ga-FAPi-46) in normal and cancer tissues of patients with various malignancies.

SECONDARY OBJECTIVES:

I. To evaluate the degree of 68Ga-FAPi-46 accumulation observed by positron emission tomography (PET) imaging as opposed to the amount of FAP in excised cancer tissue.

II. To assess the 68Ga-FAPI-46 biodistribution correlation with 18F-FDG biodistribution and to define the frequency of the following phenotypes (FAP+/ FDG+, FAP-/ FDG+, FAP+/ FDG-, FAP-/ FDG-)

EXPERIMENTAL OBJECTIVE:

To assess the correlation of 68Ga-FAPI-46 biodistribution with 68Ga-DOTATATE or 18F-DOPA (FDOPA), depending on the specific indication in patients who had them available

OUTLINE:

Patients receive 68Ga-FAPi-46 intravenously (IV), and then undergo PET/computed tomography (CT) over 20-90 minutes. On another day, patients receive 18F-FDG and then undergo PET/computed tomography (CT) according to standard of care procedures (if applicable).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients with the following cancer types:

Brain cancer
Bladder cancer
Urothelial cancer
Testicular cancer
Skin cancer
Thyroid cancer
Hepatocellular carcinoma
Cholangiocarcinoma
Thymus cancer
Pleural cancer
Cervical cancer
Adrenal cancer
Neuroendocrine tumors
Hematologic cancer
Patients who are scheduled to undergo surgical resection or tissue biopsy of the primary tumor and/or metastasis
Patients are ≥ 18 years old at the time of the radiotracer administration.
Patient can provide written informed consent
Patient is able to remain still for duration of imaging procedure (up to one hour)

Exclusion Criteria:

Patient is pregnant or nursing
Patients with any new cancer therapy between the baseline PET/CT and the investigational FAPI PET/CT
Patient has underlying disease which, based on the judgment of the investigator, might interfere with the collection of high quality data

Study is for people with:

Bladder Cancer

Phase:

Phase 1

Estimated Enrollment:

30

Study ID:

NCT04459273

Recruitment Status:

Recruiting

Sponsor:

Jonsson Comprehensive Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

UCLA / Jonsson Comprehensive Cancer Center
Los Angeles California, 90095, United States More Info
Andrea Limon
Contact
310-206-7372
[email protected]
Rejah Marie Alano
Contact
310-206-7372
[email protected]
Jeremie Calais
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Bladder Cancer

Phase:

Phase 1

Estimated Enrollment:

30

Study ID:

NCT04459273

Recruitment Status:

Recruiting

Sponsor:


Jonsson Comprehensive Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.